RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for the use of KEYTRUDA, its anti-PD-1 therapy, for two gynecologic cancer indications. The CHMP has recommended approval of KEYTRUDA in combination with chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma who are eligible for systemic therapy. Additionally, KEYTRUDA in combination with chemoradiotherapy is recommended for the treatment of locally advanced cervical cancer in adults who have not received prior definitive therapy.
These recommendations are based on the outcomes of the Phase 3 NRG-GY018 trial, also known as KEYNOTE-868, and the Phase 3 KEYNOTE-A18 trial. In the NRG-GY018 trial, the KEYTRUDA regimen showed a statistically significant and clinically meaningful improvement in progression-free survival compared to placebo plus chemotherapy for endometrial carcinoma. The KEYNOTE-A18 trial demonstrated similar improvements in overall survival and progression-free survival for cervical cancer when KEYTRUDA was combined with concurrent chemoradiotherapy, compared to CRT alone.
Dr. Gursel Aktan, vice president of global clinical development at Merck Research Laboratories, expressed the company's commitment to advancing the role of KEYTRUDA for patients facing challenging gynecologic cancers. The European Commission will review the CHMP's recommendations, with final marketing authorization decisions expected in the fourth quarter of 2024.
Endometrial carcinoma is the most common type of uterine cancer, ranking as the sixth most common cancer in women globally. Cervical cancer, affecting the cells lining the cervix, is the fourth most common cancer in women worldwide. Both cancers represent significant health challenges, with substantial numbers of new cases and deaths occurring annually in Europe.
Merck's ongoing research in women's cancers is extensive, with more than 20 clinical trials involving over 18,000 patients worldwide. The company aims to improve outcomes for patients affected by breast and gynecologic cancers, which are the first and second most commonly occurring cancer types among women globally. Merck's research includes evaluating its medicines in earlier stages and exploring novel mechanisms and combinations to advance care in women's cancers.
This news is based on a press release statement and has not been independently verified. The information provided does not endorse the company or its products/services. Relevant data and statistics mentioned are pertinent to the news story and sourced from the press release itself.
In other recent news, Merck & Co. has made significant strides in the healthcare sector. The U.S. Food and Drug Administration has approved Merck's immunotherapy drug, KEYTRUDA, for the treatment of advanced malignant pleural mesothelioma. This approval is based on the Phase 3 IND.227/KEYNOTE-483 trial results, which indicated that KEYTRUDA, in combination with chemotherapy, improved overall survival rates.
In addition, Merck's GARDASIL®9 HPV vaccine trial met both primary and secondary endpoints, demonstrating efficacy in reducing the incidence of persistent anogenital infection. The company's second-quarter results for 2024 exceeded market expectations, leading to an upward revision of its full-year 2024 guidance. TD Cowen maintained a Buy rating on Merck, indicating confidence in the company's potential for growth.
The company also initiated the BRUNELLO trial for its investigational drug Restoret (MK-3000), aimed at treating diabetic macular edema. However, two Phase 3 trials, KEYNOTE-867 and KEYNOTE-630, were halted due to insufficient efficacy of KEYTRUDA in treating non-small cell lung cancer and cutaneous squamous cell carcinoma.
The European Commission approved Merck's anti-PD-1 therapy KEYTRUDA, in combination with Padcev, for the treatment of unresectable or metastatic urothelial carcinoma, marking the third bladder cancer indication for KEYTRUDA in the EU. The European Commission also approved Merck's therapy, WINREVAIR, for the treatment of pulmonary arterial hypertension. These are the recent developments in Merck & Co.'s operations.
InvestingPro Insights
As Merck & Co. (NYSE:MRK) receives favorable opinions from the European Medicines Agency for its KEYTRUDA therapy, investors may find the company's financial health and market performance to be of interest. Merck, a leading pharmaceutical company, is not only advancing in the medical field but also showing robust financial metrics that could be compelling for stakeholders.
InvestingPro data highlights Merck's strong market presence with a significant market capitalization of $297.16 billion, underscoring its substantial size and influence in the pharmaceutical industry. The company's Price/Earnings (P/E) ratio stands at a solid 21.68, with an adjusted P/E ratio for the last twelve months as of Q2 2024 at 17.91, suggesting that investors may find the stock reasonably valued based on its earnings. Additionally, Merck's revenue growth remains positive, with a 7.15% increase over the last twelve months as of Q2 2024, indicating a healthy expansion in its business operations.
InvestingPro Tips for Merck also provide valuable insights. The company has a history of rewarding its shareholders, having raised its dividend for 13 consecutive years and maintaining dividend payments for 54 consecutive years. This consistent return to shareholders may be particularly attractive to income-focused investors. Furthermore, Merck is expected to see net income growth this year, which could signal further financial strength and stability for the company.
For investors seeking a deeper analysis, there are additional InvestingPro Tips available at https://www.investing.com/pro/MRK, providing a more comprehensive look at Merck's financial health and market prospects.
The company's advancements in treatments for gynecologic cancers, such as KEYTRUDA, are not only a stride forward in medicine but also reflect Merck's commitment to innovation and its potential for sustained growth, which might be of interest to both healthcare professionals and investors alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.